$1.2 billion! Roche shares in foundation medicine

Source: Biovalley on January 13, 2015, pharmaceutical giant Roche recently announced that the company has reached cooperation intention with foundationmedicine, a molecular diagnosis company Roche will take a stake in foundationmedicine as one of the major shareholders to participate in the daily management of the company According to the agreement, Roche will pay foundation medicine $780 million at a price of $50 per share, which is nearly twice the price of its share price last Friday At the same time, the company purchased an additional $250 million worth of shares at the same price These investments, together with the $150 million previously invested by Roche and foundationmedicine, enabled Roche to acquire 56% of its shares and become the true owner of foundationmedicine Through this agreement, Roche's biggest purpose of becoming a shareholder of foundation medicine is to use its advanced sequencing technology to clear the way for the company to develop personalized cancer treatment in the future Foundation medicine has been committed to the development of cancer gene detection technology since its establishment As we all know, if doctors can detect the occurrence of cancer in the early stage, it has an immeasurable effect on the early treatment of cancer Roche, one of the most wealthy local entrepreneurs in the field of biomedicine, surprised some people this time Since 2014, there has been a rare acquisition frenzy in the biomedical market Roche did not choose the "simple and crude" method of acquisition and merger this time, but took the form of equity investment, which is indeed some alternative On the other hand, foundation medicine also expressed satisfaction with the agreement The company's senior management believed that the capital injection of Roche would accelerate the company's development in the field of molecular diagnosis In the future, the two sides will establish closer cooperation in the field of tumor DNA detection technology.